Literature DB >> 27816997

Gamma Knife radiosurgery for neurofibromatosis type 2-associated meningiomas: a 22-year patient series.

Brandon Birckhead1, Terence T Sio2, Bruce E Pollock3, Michael J Link3, Nadia N Laack4.   

Abstract

Neurofibromatosis type 2 (NF2) is a debilitating genetic condition with potential development of multiple meningiomas. We report our experience treating a series of NF2-associated intracranial meningiomas with Gamma Knife radiosurgery (GKRS). Between 1992 and 2013, 15 consecutive patients (age 20-54 years) with 62 intracranial meningiomas were treated with single-fraction GKRS. Fifty-five percent of tumors involved the convexity or parasagittal/falx. The median prescription dose was 16 Gy (range 13-20 Gy). The median tumor diameter was 2.1 cm (range 0.7-4.5 cm). The median radiographic and clinical follow-up periods were 103 and 111 months, respectively. The 5-year and 10-year local controls were both 96 %. The disease specific survival was 93 % at 5 years and 68 % at 10 years. Fifty-three percent of patients had multiple meningiomas and received multiple GKRS treatments (range 1-7) for new or enlarging intracranial meningiomas. 11 (73 %) patients were alive at last follow-up, with 60 (97 %) tumors controlled (smaller or unchanged in size). There were 2 in-field failures, one at 1 year and the other at 3.5 years. There were no marginal failures. Major Complications after GKRS included: 1 case of radiation necrosis, 1 case of post treatment edema, and 1 case of a presumed radiation induced cavernous malformation 5 years after GKRS. GK is an effective treatment for enlarging NF2-associated meningiomas. No cases of malignant transformation or secondary malignancies were seen during the follow-up period.

Entities:  

Keywords:  Gamma Knife; Meningioma; Neurofibromatosis; Radiotherapy; Stereotactic radiosurgery

Mesh:

Substances:

Year:  2016        PMID: 27816997     DOI: 10.1007/s11060-016-2257-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

2.  Judicious resection and/or radiosurgery for parasagittal meningiomas: outcomes from a multicenter review. Gamma Knife Meningioma Study Group.

Authors:  D Kondziolka; J C Flickinger; B Perez
Journal:  Neurosurgery       Date:  1998-09       Impact factor: 4.654

3.  High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results.

Authors:  J Debus; M Wuendrich; A Pirzkall; A Hoess; W Schlegel; I Zuna; R Engenhart-Cabillic; M Wannenmacher
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

4.  Predictors of peritumoral edema after stereotactic radiosurgery of supratentorial meningiomas.

Authors:  Chirag G Patil; Stanley Hoang; D John Borchers; Gordon Sakamoto; Scott G Soltys; Iris C Gibbs; Griffith R Harsh; Steven D Chang; John R Adler
Journal:  Neurosurgery       Date:  2008-09       Impact factor: 4.654

Review 5.  Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990.

Authors:  B J Goldsmith; W M Wara; C B Wilson; D A Larson
Journal:  J Neurosurg       Date:  1994-02       Impact factor: 5.115

6.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

7.  Radiosurgery as definitive management of intracranial meningiomas.

Authors:  Douglas Kondziolka; David Mathieu; L Dade Lunsford; Juan J Martin; Ricky Madhok; Ajay Niranjan; John C Flickinger
Journal:  Neurosurgery       Date:  2008-01       Impact factor: 4.654

8.  Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity.

Authors:  D M Parry; R Eldridge; M I Kaiser-Kupfer; E A Bouzas; A Pikus; N Patronas
Journal:  Am J Med Genet       Date:  1994-10-01

9.  Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2.

Authors:  Ann Liu; Elizabeth N Kuhn; John T Lucas; Adrian W Laxton; Stephen B Tatter; Michael D Chan
Journal:  J Neurosurg       Date:  2015-01-02       Impact factor: 5.408

10.  Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy.

Authors:  Teresa Stachowicz-Stencel; Anna Synakiewicz; Ewa Bien; Elzbieta Adamkiewicz-Drozynska; Miroslawa Wybieralska-Dubaniewicz; Anna Balcerska
Journal:  Childs Nerv Syst       Date:  2010-07-27       Impact factor: 1.475

View more
  3 in total

1.  Skull Base Meningiomas in Patients with Neurofibromatosis Type 2: An International Multicenter Study Evaluating Stereotactic Radiosurgery.

Authors:  Henry Ruiz-Garcia; Daniel M Trifiletti; Nasser Mohammed; Yi-Chieh Hung; Zhiyuan Xu; Tomas Chytka; Roman Liscak; Manjul Tripathi; David Arsanious; Christopher P Cifarelli; Marco Perez Caceres; David Mathieu; Herwin Speckter; Gautam U Mehta; Gregory P Lekovic; Jason P Sheehan
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

2.  Secondary malignancy following stereotactic radiosurgery for benign neurologic disease: A cohort study and review of the literature.

Authors:  Alexander D Sherry; Brian Bingham; Ellen Kim; Meredith Monsour; Guozhen Luo; Albert Attia; Lola B Chambless; Anthony J Cmelak
Journal:  J Radiosurg SBRT       Date:  2020

3.  Convexity Meningiomas in Patients with Neurofibromatosis Type 2: Long-Term Outcomes After Gamma Knife Radiosurgery.

Authors:  Henry Ruiz-Garcia; Daniel M Trifiletti; Nasser Mohammed; Yi-Chieh Hung; Zhiyuan Xu; Tomas Chytka; Roman Liscak; Manjul Tripathi; David Arsanious; Christopher P Cifarelli; Marco Perez Caceres; David Mathieu; Herwin Speckter; Gregory P Lekovic; Gautam U Mehta; Jason P Sheehan
Journal:  World Neurosurg       Date:  2020-11-03       Impact factor: 2.104

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.